Dr. Reddy's Laboratories recalled 4,800 bottles of Varenicline tablets on November 11, 2025, due to sub potent drug levels. The affected lot failed stability tests, posing potential health risks to users. Consumers should stop using the product immediately and consult healthcare providers.
Sub potent drug: during the 9-month stability test conducted, the assay value for the affected lot was below specification limit.
Consumers and healthcare providers should stop using this product immediately. Contact Dr. Reddy's Laboratories, Inc. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall affects Varenicline Tablets, 1mg, 56 tablets per bottle, distributed nationwide. The affected lot number is F2400244, with an expiration date of October 31, 2026.
The recall involves a sub potent drug, which means the active ingredient may not be effective. The assay value for the affected lot fell below the specification limit during a 9-month stability test.
No reported incidents, injuries, or deaths related to this recall have been mentioned. Users are advised to stop use to avoid potential health risks.
Stop using Varenicline tablets immediately. Contact Dr. Reddy's Laboratories or your healthcare provider for further guidance and potential alternatives.
For more information, contact Dr. Reddy's Laboratories at their official website or customer service line. Additional details are available at the FDA recall page.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.